Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-p53 Combined with Chemotherapy Treatment
Human Gene Therapy, Ahead of Print.
Publication date: May–June 2020Source: Journal of Minimally Invasive Gynecology, Volume 27, Issue 4Author(s): Scott E. Lentz, Eve Zaritsky, Lue-Yen Tucker, Catherine Lee, Isabel M. Lazo, Aki Niihara, Miya Yamamoto, Tina Raine-Bennett
CONCLUSIONS: Prospective genomic profiling can contribute to diagnostic precision and inform treatment selection in patients with uterine sarcomas. There was evidence of clinical benefit in uLMS patients with somatic BRCA2 alterations treated with PARP inhibitors. PMID: 32299819 [PubMed - as supplied by publisher]
In this study, a new set of 1,4,5,6,7,8-hexahydro 5-oxo quinoline-3-carboxamide derivatives bearing 4-methylthiazole moiety and their tetrahydroquinoline counterparts were synthesized. MDR reversal activity of these 16 newly synthesized derivatives was tested in P-gp overexpressing MES-SA-DX5 human uterine sarcoma cells by flow cytometric determination of Rhodamine123 efflux. The effect of the most potent compounds in induction of apoptosis and alterations of cell cycle was examined in these cells by a flow cytometric method. Inherent cytotoxicity of the synthesized compounds was evaluated against MCF-7, A-549 and K562 can...
The decreasing costs of next generation sequencing technologies and greater acceptance of molecular and biologic findings into the pathology domain, have shifted our paradigms of classification for many gynecologic tumors. This review focuses on major molecular developments within the last 5 years in endometrial carcinoma, endocervical adenocarcinoma, vulvar squamous cell carcinoma and uterine sarcoma, and the emergence of molecular subgroups within each family of tumors.
Authors: Sierra-Labarta CR, Ibáñez-Muñoz D, Aranda-Lozano J, De Pablo-Cárdenas Á, Cuesta-Alcalá JÁ, Sánchez-Zalabardo D PMID: 32240117 [PubMed - in process]
To investigate clinical parameters combined with magnetic resonance imaging (MRI) features including apparent diffusion coefficient (ADC) values in preoperative identification of different subtypes of uterine sarcomas including uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), and carcinosarcoma (CS). Data from 71 patients with uterine sarcoma confirmed by surgery and pathology were collected. The clinical characteristics, conventional MRI features, mean ADC values, minimum ADC values, and lesion-muscle ADC ratio (rADC) values were compared with different subtypes of uterine sarcomas. Age, clinical manifes...
e;n Z Abstract Germinal or somatic mutations of the BRCA genes may serve as therapeutic targets. Deficient functioning of the BRCA genes render the cancer vulnerable to such therapeutic interventions as chemotherapy with DNA-targeted agents and PARP inhibitors targeting DNA repair capacity. Although BRCA mutations may be detected in a large variety of cancers, the mentioned specific therapies are efficient in the so called BRCA-associated cancers only including ovarian, breast, pancreatic, prostate cancers and the rare uterine sarcomas. While in ovarian and prostate carcinomas both germinal and somatic, in breast ...
CONCLUSIONS: Alterations of CDK4 pathway members, for which targeted therapy is clinically available (i.e. palbociclib), via CDK4 amplification or CDKN2A loss, contributes to the pathogenesis of BCOR-rearranged uterine sarcomas, which may have therapeutic implications. PMID: 32156473 [PubMed - as supplied by publisher]
CONCLUSION: All these described pathologies have no specific clinic characteristics; the most common symptom is abnormal uterine bleeding. To date, hysterectomy and bilateral salpingo-oophorectomy are the standards of care in the management of all early stage uterine sarcomas. To our knowledge, cases of LMS, ESS and cavernous haemangioma coexisting in the same patient have not been reported in literature to date. The pathogenesis of this combination remains to be elucidated. Key words: Cavernous hemangioma, Endometrial stromal sarcoma, Leiomyosarcoma, Uterine sarcomas. PMID: 32129176 [PubMed - in process]
Conclusion: Urinary tract resections might be needed in order to maximize the debulking effort in patients presenting endometrial stromal sarcomas.